Wehrle Chase J, Tocci Noah X, Sun Keyue, Jiao Chunbao, Hong Hanna, Gross Abby, Allkushi Erlind, Uysal Melis, Linganna Maureen Whitsett, Stackhouse Katheryn, Hashimoto Koji, Schlegel Andrea, Walsh R Matthew, Miller Charles, Kwon David C H, Aucejo Federico
Department of Hepato-Pancreato-Biliary & Liver Transplant Surgery, Cleveland Clinic Foundation, Digestive Diseases and Surgery Institute, Cleveland, Ohio, USA.
Cleveland Clinic Foundation, Lerner Research Institute, Inflammation & Immunity, Cleveland, Ohio, USA.
J Surg Oncol. 2025 Apr;131(5):888-894. doi: 10.1002/jso.27838. Epub 2024 Aug 19.
Secondary liver malignancies are a serious and challenging global health concern. Secondary metastasis to the liver is most commonly from colorectal cancer that has metastatically spread through splanchnic circulation. Metastatic diseases can portend poor prognosis due to the progressive nature typically found on detection. Improvements in detection of disease, monitoring therapy response, and monitoring for recurrence are crucial to the improvement in the management of secondary liver malignancies. Assessment of ctDNA in these patient populations poses an opportunity to impact the management of secondary liver malignancies. In this review, we aim to discuss ctDNA, the current literature, and future directions of this technology within secondary liver malignancies.
继发性肝恶性肿瘤是一个严重且具有挑战性的全球健康问题。肝脏的继发性转移最常见于通过内脏循环发生转移扩散的结直肠癌。由于在检测时通常发现的进行性特征，转移性疾病可能预示着预后不良。改善疾病检测、监测治疗反应以及监测复发对于改善继发性肝恶性肿瘤的管理至关重要。在这些患者群体中评估循环肿瘤DNA（ctDNA）为影响继发性肝恶性肿瘤的管理提供了一个契机。在本综述中，我们旨在讨论ctDNA、当前的文献以及该技术在继发性肝恶性肿瘤中的未来发展方向。
